Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLOD2 | O00469 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.58 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.58 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.53 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL11040809 | 0.98 | PLOD2 (0.67) | PLOD2KMT2ALMNATDP1GAA | |
| Hydrochloric Acid SCHEMBL11169565 | 0.98 | PLOD2 (0.67) | PLOD2KMT2ALMNATDP1GAA | |
| SCHEMBL17672056 | 0.91 | NAPRT (0.65) | PLOD2KMT2ALMNATDP1GAA | |
| SCHEMBL31326722 | 0.91 | NAPRT (0.65) | PLOD2KMT2ALMNATDP1GAA | |
| SCHEMBL3059074 | 0.89 | PLOD2 (0.59) | PLOD2KMT2ALMNATDP1GAA | |
| SCHEMBL1515767 | 0.89 | NAPRT (0.68) | PLOD2KMT2ALMNATDP1GAA | |
| Hydrochloric Acid SCHEMBL27958148 | 0.88 | NAPRT (0.66) | PLOD2KMT2ALMNATDP1GAA | |
| SCHEMBL4744539 | 0.86 | PLOD2 (0.56) | PLOD2KMT2ALMNATDP1GAA | |
| SCHEMBL6501915 | 0.86 | RAB9A (0.66) | PLOD2KMT2ALMNATDP1GAA | |
| SCHEMBL5424552 | 0.85 | MAPT (0.57) | PLOD2KMT2ALMNAGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582690-B1 | PROCESS FOR PREPARATION OF 2, 3-DIARYL-5-SUBSTITUTED PYRIDINES AND THEIR INTERMEDIATES | GLENMARK GENERICS LTD (IN) | 2018-07-25 | — | — | EP | disclosed |
| US-9283229-B2 | Dihydropyrimidin-2(1H)-one compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-9283213-B2 | Dihydropyridin-2(1H)-one compounds as S-nitrosoglutathione reductase inhibitors and neurokinin-3 receptor antagonists | NIVALIS THERAPEUTICS, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| EP-2592934-B1 | NOVEL DIHYDROPYRIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS AND NEUROKININ-3 RECEPTOR ANTAGONISTS | NIVALIS THERAPEUTICS INC (US) | 2015-08-26 | — | — | EP | disclosed |
| US-20150224107-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2015-08-13 | — | — | US | disclosed |
| US-9067893-B2 | Dihydropyrimidin-2(1H)-one compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20150157616-A1 | Novel Dihydropyridin-2(1H)-One Compounds as S-Nitrosoglutathione Reductase Inhibitors and Neurokinin-3 Receptor Antagonists | NIVALIS THERAPEUTICS, INC. | 2015-06-11 | — | — | US | disclosed |
| US-8946434-B2 | Dihydropyridin-2(1H)-one compound as S-nirtosoglutathione reductase inhibitors and neurokinin-3 receptor antagonists | N30 PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140235640-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8741915-B2 | Dihydropyrimidin-2(1H)-one compounds as S-nitrosoglutathione reductase inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-0082111-A2 | Process for the preparation of imidazoles | CIBA-GEIGY AG (CH) | 1983-06-22 | — | — | EP | disclosed |
| EP-0004648-B1 | MERCAPTO-IMIDAZOLE DERIVATIVES, THEIR PREPARATION, MERCAPTO-IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES AND THEIR PHARMACEUTICAL COMPOSITIONS | CIBA-GEIGY AG (CH) | 1982-08-25 | — | — | EP | disclosed |
| EP-0046451-A2 | Diaryl-imidazole compounds, methods for their preparation, pharmaceutical drugs containing them and their use | CIBA-GEIGY AG (CH) | 1982-02-24 | — | — | EP | disclosed |
| EP-0045081-A2 | Trisubstituted imidazole derivatives, processes for preparing them, pharmaceutical compositions containing them, and their use | CIBA-GEIGY AG (CH) | 1982-02-03 | — | — | EP | disclosed |
| US-4308277-A | IMMUNOREGULATORY, ANTITHROMBOTIC, ANTIINFLAMMATORY | CIBA-GEIGY CORPORATION (US) | 1981-12-29 | — | — | US | disclosed |
| EP-0019688-A1 | Diaza compounds and process for their preparation | CIBA-GEIGY AG (CH) | 1980-12-10 | — | — | EP | disclosed |
| EP-0004648-A2 | Mercapto-imidazole derivatives, their preparation, mercapto-imidazole derivatives for the treatment of inflammatory diseases and their pharmaceutical compositions | CIBA-GEIGY AG (CH) | 1979-10-17 | — | — | EP | disclosed |
| US-4159338-A | ANTIARTHRITIC, ANALGESIC | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1979-06-26 | — | — | US | disclosed |
| US-4128651-A | Bis-quaternary pyridinium-2-aldoxime salts and a process for their preparation | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1978-12-05 | — | — | US | disclosed |
| US-3940486-A | Imidazole derivatives in the treatment of pain | CIBA-GEIGY CORPORATION (US) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235640-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | QDPR, GSR, CBR1 | PLOD2 2431/4885KMT2A 3962/4885LMNA 4560/4885 |
| US-20150157616-A1 | Novel Dihydropyridin-2(1H)-One Compounds as S-Nitrosoglutathione Reductase Inhibitors and Neurokinin-3 Receptor Antagonists | QDPR, TACR1, TACR2 | PLOD2 3911/4885KMT2A 2740/4885LMNA 4628/4885 |
| US-20150224107-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | QDPR, GSR, CBR1 | PLOD2 2431/4885KMT2A 3962/4885LMNA 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.